---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-000964"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:12:27.388936+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab Corp. completes Chemrex governance restructuring; appoints Matthew Barsing as Chairman

## Summary
- Chemrex board streamlined to two directors: Matthew L. Barsing (Chairman) and Angeline Chong (Director, BioNexus CFO).
- New officers expected in coming months; Chemrex remains wholly owned subsidiary under parent oversight.
- July 2025 capital allocation framework approved for potential operational upgrades, subject to evaluation.
- No definitive commitments on scope, timing, or scale of any initiative under evaluation.

## SEC filing metadata
- accession: 0001477932-26-000964
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793226000964/0001477932-26-000964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793226000964/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-000964
- JSON: https://secwatch.observer/filing/0001477932-26-000964.json
- Plain text: https://secwatch.observer/filing/0001477932-26-000964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.